```
=> d l1; d his; log y
L1 HAS NO ANSWERS
L1              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

     (FILE 'HOME' ENTERED AT 15:40:12 ON 23 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 15:40:32 ON 23 JUL 2003
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            7 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 15:41:11 ON 23 JUL 2003
L4            3 S L3

     FILE 'BEILSTEIN' ENTERED AT 15:41:47 ON 23 JUL 2003
L5            2 S L1 FUL
L6            2 S L5 NOT L4

     FILE 'MARPAT' ENTERED AT 15:42:32 ON 23 JUL 2003
L7            0 S L1
L8            2 S L1 FUL
L9            0 S L8 NOT L4


COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                           104.55     325.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                               ENTRY    SESSION
CA SUBSCRIBER PRICE                             0.00      -1.95

STN INTERNATIONAL LOGOFF AT 15:43:08 ON 23 JUL 2003
```

C:\Program Files\Stnexp\Queries\10019804.str



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:487542 CAPLUS
DN 137:63247
TI Preparation of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides for treatment of cartilage disorders
IN Madelmont, Jean-Claude; Giraud, Isabelle; Vidal, Aurelien; Mounetou, Emmanuelle; Rapp, Maryse; Maurizis, Jean-Claude; Renard, Pierre; Caignard, Daniel-Henri; Bizot-Espiard, Jean-Guy
PA Les Laboratoires Servier, Fr.; Institut National De La Recherche Medicale
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050049	A1	20020627	WO 2001-FR4135	20011221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	FR 2818641	A1	20020628	FR 2000-16739	20001221
	AU 2002028120	A5	20020701	AU 2002-28120	20011221
PRAI	FR 2000-16739	A	20001221		
	WO 2001-FR4135	W	20011221		

OS CASREACT 137:63247; MARPAT 137:63247
GI



I

AB Title compds. [(un)substituted I; R = NHZNR5R6R7X; R1 = H, OH, alkoxy, etc.; R2 = H or alkyl; R5-R7 = alkyl or 2 of R5-R7 = atoms to complete a ring and the other = alkyl; X = halo; Z = alkylene; dashed line = optional addnl. bond] were prepd. Thus, I (R1 = OH, R2 = Me)(II; R = OMe) was amidated by H2N(CH2)3NEt2 and the product quaternized to give II [R = NH(CH2)3NMeEt2I]. Data for biol. activity of I were given.
IT **439254-42-9P 439254-44-1P 439254-46-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(prepn. of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides for treatment of cartilage disorders)
RN 439254-42-9 CAPLUS
CN 1-Propanaminium, N,N-diethyl-3-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 439254-44-1 CAPLUS

CN 1-Propanaminium, N,N,N-triethyl-3-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 439254-46-3 CAPLUS

CN 1-Butanaminium, 4-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:12454 CAPLUS
DN 134:71584
TI Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use for treatment or diagnosis of pathologies affecting cartilage
IN Madelmont, Jean-claude; Giraud, Isabelle; Nicolas, Colette; Maurizis, Jean-claude; Rapp, Maryse; Ollier, Monique; Renard, Pierre; Caignard, Daniel-henri
PA Adir Et Compagnie, Fr.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000621	A1	20010104	WO 2000-FR1731	20000622
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2795412	A1	20001229	FR 1999-8020	19990623
	FR 2795412	B1	20010713		
	EP 1185526	A1	20020313	EP 2000-945979	20000622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000011943	A	20020514	BR 2000-11943	20000622
	JP 2003503407	T2	20030128	JP 2001-507029	20000622
	NO 2001006267	A	20020130	NO 2001-6267	20011220
PRAI	FR 1999-8020	A	19990623		
	WO 2000-FR1731	W	20000622		

OS MARPAT 134:71584
AB The invention concerns compds. [M-(X)n-N+R1R2R3]Hal- (Ia) wherein M = a mol. for use in the treatment or diagnosis of pathologies affecting cartilage; R1, R2, R3 = alkyl group, or R1, R2, R3 together with the N atom which bears them form a heterocycle; X = C1-C6 alkyl chain wherein one or several -CH2- groups are optionally substituted by S, O, -NR, -CO-, -CO-NH-, -CO2-, SO- or SO2- group; n = 0 or 1; Hal- = halide, or [(A)(B)(C)N+R4]Hal- (Ib) in which R4 = linear or branched C1-6 alkyl groups, Hal- = halide, and general formula (A)(B)(C)N (F1) represents a mol. for use in the treatment or diagnosis of pathologies affecting cartilage, provided that the N atom can optionally be included in a satd. or unsatd. nitrogenous heterocyclic system, or involved in a double bond. Pathologies of cartilage affected by treatment with compds. Ia and Ib may include use as anti-inflammatories, analgesics, anti-osteoarthritics, antiarthritics, and antitumor agents. More specific structures for [M-(X)n-N+R1R2R3]Hal- (Ia) are also claimed where M = derivs. of Tenidap, Melphalan, Chlorambucil, or glucosamine, and for structure Ib which includes Piroxicam derivs. A dioxotechnetium complex of a 1,4,7,10,13-pentaazacyclopentadecane deriv. is also claimed and a prepn. is given. Processes for the prepn. of the compds. are also claimed and

example prepns. are provided, e.g., via a peptide coupling reaction.

IT **256419-19-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(prepn. and use of quaternary ammonium halides for treatment or diagnosis of pathologies affecting cartilage, and biodistribution in rat)

RN 256419-19-9 CAPLUS

CN 1-Propanaminium, 3-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

IT **256419-17-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of quaternary ammonium halides for treatment or diagnosis of pathologies affecting cartilage, and biodistribution in rat)

RN 256419-17-7 CAPLUS

CN Pyridinium, 2-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:757962 CAPLUS
DN 132:117300
TI New Quaternary Ammonium Oxicam Derivatives Targeted toward Cartilage: Synthesis, Pharmacokinetic Studies, and Antiinflammatory Potency
AU Nicolas, Colette; Verny, Michel; Giraud, Isabelle; Ollier, Monique; Rapp, Maryse; Maurizis, Jean-Claude; Madelmont, Jean-Claude
CS INSERM Unite 484, Clermont-Ferrand, 63005, Fr.
SO Journal of Medicinal Chemistry (1999), 42(25), 5235-5240
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Analogs of nonsteroidal antiinflammatory drugs (NSAIDs) oxicams, in which the active group was linked to a quaternary ammonium function [(4-hydroxy-2-methyl-2H-1,2-benzothiazine-1,1-dioxide-3-carboxamido)2-methylpyridinium iodide or piroxicam-N+ and [3-(4-hydroxy-2-methyl-2H-1,2-benzothiazine-1,1-dioxide-3-carboxamido)propyl]trimethylammonium iodide or propoxicam-N+] were synthesized. Compds. were labeled with tritium for piroxicam-N+ and carbon-14 for propoxicam-N+. Pharmacokinetic studies conducted on rats showed that these mols. were able to highly conc. in joint cartilages but their bioavailability by the oral route was low. Only propoxicam-N+ exhibited a sufficient water soly. to be administered i.v. This mol. was able to restore proteoglycans biosynthesis in cultured articular chondrocytes treated with Interleukin-1.beta. with an efficiency identical to that of indomethacin. These results suggest that the functionalization of oxicam derivs. by a quaternary ammonium group greatly increases their affinity toward articular cartilage without eliminating their pharmacol. activity. New drugs synthesized according to this scheme could be useful to obtain a significant decrease of the efficient administered dose and consequently an attenuation of adverse effects such as digestive toxicity.
IT **256419-17-7 256419-19-9**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(new quaternary ammonium oxicam derivs. targeted toward cartilage in relation to synthesis and pharmacokinetic studies and antiinflammatory potency detd. as inhibition of proteoglycan synthesis)
RN 256419-17-7 CAPLUS
CN Pyridinium, 2-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 256419-19-9 CAPLUS
CN 1-Propanaminium, 3-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA

INDEX NAME)



IT **256419-26-8P 256419-32-6P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)(new quaternary ammonium oxicam derivs. targeted toward cartilage in relation to synthesis and pharmacokinetic studies and antiinflammatory potency detd. as inhibition of proteoglycan synthesis)

RN 256419-26-8 CAPLUS

CN Pyridinium, 2-[[[4-hydroxy-2-(methyl-t3)-1,1-dioxido-2H-1,2-benzothiazin-3-yl]carbonyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



RN 256419-32-6 CAPLUS

CN 1-Propanaminium, 3-[[(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl-14C]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN



CM 2

FBRN 3587184
FMF I

Reference(s):
1. Nicolas, Colette; Verny, Michel; Giraud, Isabelle; Ollier, Monique; Rapp, Maryse; Maurizis, Jean-Claude; Madelmont, Jean-Claude, J.Med.Chem., CODEN: JMCMAR, 42(25), <1999>, 5235 - 5240; BABS-6228165

L6 ANSWER 2 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN



Reference(s):

1. Reymond, Frederic; Steyaert, Guillaume; Pagliara, Alessandra; Carrupt, Pierre-Alain; Testa, Bernard; Girault, Hubert, Helv.Chim.Acta, CODEN: HCACAV, 79(6), <1996>, 1651-1669; BABS-6020103

QD1.44

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2003 ACS on STN
AN 137:63247 MARPAT
TI Preparation of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides for treatment of cartilage disorders
IN Madelmont, Jean-Claude; Giraud, Isabelle; Vidal, Aurelien; Mounetou, Emmanuelle; Rapp, Maryse; Maurizis, Jean-Claude; Renard, Pierre; Caignard, Daniel-Henri; Bizot-Espiard, Jean-Guy
PA Les Laboratoires Servier, Fr.; Institut National De La Recherche Medicale
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050049	A1	20020627	WO 2001-FR4135	20011221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	FR 2818641	A1	20020628	FR 2000-16739	20001221
	AU 2002028120	A5	20020701	AU 2002-28120	20011221
PRAI	FR 2000-16739	20001221			
	WO 2001-FR4135	20011221			

OS CASREACT 137:63247
GI



I

AB Title compds. [(un)substituted I; R = NHZNR5R6R7X; R1 = H, OH, alkoxy, etc.; R2 = H or alkyl; R5-R7 = alkyl or 2 of R5-R7 = atoms to complete a ring and the other = alkyl; X = halo; Z = alkylene; dashed line = optional addnl. bond] were prepd. Thus, I (R1 = OH, R2 = Me)(II; R = OMe) was amidated by H2N(CH2)3NEt2 and the product quaternized to give II [R = NH(CH2)3NMeEt2I]. Data for biol. activity of I were given.

MSTR 1



G9

G3 = OH
G6 = alkylene<(1-6)>
G7 = 26



G8 = alkyl<(1-6)>
G10 = alkyl<(1-6)>
MPL: claim 1
NTE: substitution is restricted
STE: and isomers

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:36:29 ON 23 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:36:36 ON 23 JUL 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 15:37:02 ON 23 JUL 2003
L4 0 S L1
L5 1 S L1 FUL

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.78	257.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 15:37:46 ON 23 JUL 2003

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:26751 CAPLUS
DN 138:368857
TI Synthesis of 3-aminohydantoinyl-1,2-benzothiazine derivatives
AU Park, Myung-Sook; Chang, Eun-Sung; Lee, Myung-Sook; Kwon, Soon-Kyoung
CS College of Pharmacy, Duksung Women's University, Seoul, 132-714, S. Korea
SO Bulletin of the Korean Chemical Society (2002), 23(12), 1836-1838
CODEN: BKCSDE; ISSN: 0253-2964
PB Korean Chemical Society
DT Journal
LA English
GI



I



II



III

AB N-dioxoimidazolidinyl hydroxybenzothiazinecarboxamides I (R = EtCH2, Bu, Me2CH, Me2CHCH2; R1 = H, Br, Cl) are prepd. as potential analgesic and antiinflammatory agents. 5-Substituted 3-aminoimidazolidinediones (3-aminohydantoins) are prepd. by cyclocondensation of L-amino acids and tert-Bu carbazate in quinoline. Alkylation of the sodium salts of saccharins II (R1 = H, Br, Cl) with Me chloroacetate followed by ring expansion in the presence of sodium methoxide in methanol gives dioxobenzothiazinecarboxylates III (R1 = H, Br, Cl). Amidation of III (R1 = H, Br, Cl) with 5-substituted 3-aminohydantoins provides the title compds. I (R = EtCH2, Bu, Me2CH, Me2CHCH2; R1 = H, Br, Cl) in three steps from saccharins II. I (R = EtCH2, Bu, Me2CH, Me2CHCH2; R1 = H, Br, Cl) show analgesic and antiinflammatory activities (no data).

IT **524707-42-4P 524707-44-6P 524707-46-8P**
524707-48-0P 524707-50-4P 524707-52-6P
524707-54-8P 524707-56-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of N-dioxoimidazolidinyl dioxobenzothiazinecarboxamides from saccharin sodium salts and 3-aminohydantoins and their potential analgesic and antiinflammatory activities)

RN 524707-42-4 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-N-(2,5-dioxo-4-propyl-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-44-6 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-butyl-2,5-dioxo-1-imidazolidinyl)-
7-chloro-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-46-8 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-(1-methylethyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-48-0 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-(2-methylpropyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-50-4 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-(2,5-dioxo-4-propyl-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-52-6 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-(4-butyl-2,5-dioxo-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-54-8 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-(1-methylethyl)-
2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-56-0 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-(2-methylpropyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:654165 CAPLUS
DN 133:358999
TI Studies on synthetic 1,2-benzothiazine anti-inflammatory agents: pharmacological effect and the expression of xenobiotic-metabolizing enzymes
AU Kim, Sang Geon; Cho, Joo Youn; Kwon, Soon-Kyung; Lee, Eun Bang
CS College of Pharmacy, Seoul National University, S. Korea
SO Yakhak Hoechi (2000), 44(4), 300-307
CODEN: YAHOA3; ISSN: 0513-4234
PB Pharmaceutical Society of Korea
DT Journal
LA Korean
AB Expression of xenobiotic-metabolizing enzymes can be altered by xenobiotics, which represent changes in the prodn. of reactive metabolic intermediates as well as toxicities in tissues. Metabolic intermediates derived from xenobiotics are considered to produce the reactive oxygen species including drug free radicals and hydroxyl free radicals, which would be ultimately responsible for drug-induced toxicities. The effects of 1,2-benzothiazine anti-inflammatory agents on the expression of xenobiotic-metabolizing enzymes including major cytochrome P450s, microsomal epoxide hydrolase (mEH) and glutathione S-transferase (GST) were studied in the liver with the aim of providing the part of information on potential prodn. of reactive metabolites and hepatotoxicity by the agents. The synthetic compds. 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (I), 7-bromo-N-[3-(4-chlorophenyl)-4-oxo-2-thioxo-1-imidazolidinyl]-4-hydroxy-2-(2-propenyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, and 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (II) exhibited anti-inflammatory effects in rats as assessed by the Randall-Selitto method. The anti-inflammatory effect was detected as early as at 30 min after gavaging the agents with the ED50 being noted at 80 mg/kg, which was comparable to that of ibuprofen. Treatment of rats with each compd. (100 mg/kg, 3d) resulted in no significant induction in the immunochem.-detectable cytochromes P 450 1A1/2, P 450 2B1/2, P 450 2C11 and P 450 2E1. Changes in the mEH expression were also minimal, as evidenced by both Western blot and Northern blot analyses. Hepatic GST expression was slightly increased by the agents: GST Ya protein and mRNA expression was .apprx.1.5-fold increased after treatment with compds. I and II, whereas GST Yb1/2 and Yc1/2 mRNA levels were elevated 2- to 3-fold. In summary, the effects of the synthetic 1,2-benzothiazines on the expression of major P 450, mEH and GST were not significant, providing evidence that metabolic activation of the agents, potential drug interaction and hepatotoxicity would be minimal.
IT **183859-52-1 183859-65-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effects of benzothiazine anti-inflammatory agents on expression of xenobiotic-metabolizing enzymes)
RN 183859-52-1 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-65-6 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:201272 CAPLUS
DN 130:338076
TI Synthesis and analgesic and anti-inflammatory activities of 1,2-benzothiazine derivatives
AU Lee, Eun Bang; Kwon, Soon Kyoung; Kim, Sang Geon
CS Natural Products Research Institute, Seoul National University, Seoul, 110-460, S. Korea
SO Archives of Pharmacal Research (1999), 22(1), 44-47
CODEN: APHRDQ; ISSN: 0253-6269
PB Pharmaceutical Society of Korea
DT Journal
LA English
GI



I

AB Three 1,2-benzothiazine derivs. I (R = H, R' = allyl, X = Cl, Br; R = allyl, R' = 4-ClC6H4, X = Br) were synthesized, and their analgesic/anti-inflammatory efficacy and their effects on gastric irritation were evaluated. Among the three compds., I (R = H, R' = allyl, X = Cl) exhibited the most potent analgesic action, but the effect was weaker than that of piroxicam. Nonetheless, the compd. showed 4 times more potent analgesic action with less gastric damage than did ibuprofen. These compds. did not show anti-inflammatory effect at an oral dose of 5 mg/kg.

IT **183859-52-1P 183859-65-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation)(prepn., analgesic, and anti-inflammatory activity of benzothiazines)

RN 183859-52-1 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-65-6 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:55223 CAPLUS
DN 126:264061
TI Studies on the activities and synthesis of N-substituted pyrimidinyl or triazinyl-3-carbamoyl-4-hydroxy-2H-1,2-benzothiazine-1,1-dioxides
AU Zhao, Guo-Feng; Zou, Xiao-Mao; Yang, Hua-Zheng
CS Inst. Elemento-Organic Chem. Nankai Univ., Tianjin, 300071, Peop. Rep. China
SO Gaodeng Xuexiao Huaxue Xuebao (1996), 17(10), 1560-1564
CODEN: KTHPDM; ISSN: 0251-0790
PB Gaodeng Jiaoyu Chubanshe
DT Journal
LA Chinese
GI



I

AB Title compds. I(R = H, Me; R1, R2 = MeO, Cl, Me) were prepd. by aminolysis of 4-hydroxy-2-hydro(methyl)-2H-1,2-benzothiazine-3-carboxylic acid Et ester 1,1-dioxides with substituted aminopyrimidines or aminotriazines. Their structures were characterized by 1H NMR, IR, MS and elementary anal. The biol. tests indicated that the majority of these compds. showed herbicidal activity and some showed plant-growth regulating activity and antiinflammatory activity.

IT **186695-73-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. activities of benzothiazine derivs.)

RN 186695-73-8 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-chloro-6-methoxy-2-pyrimidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:664323 CAPLUS
DN 126:1096
TI Some new 1,2-benzothiazine derivatives with analgesic and anti-inflammatory activities
AU Kwon, Soon Kyoung; Park, Myung Sook
CS College Pharmacy, Duk-Sung Women's University, Seoul, 132-714, S. Korea
SO Arzneimittel-Forschung (1996), 46(10), 966-971
CODEN: ARZNAD; ISSN: 0004-4172
PB Cantor
DT Journal
LA English
AB Twenty-three new 7-halo-4-hydroxy 2H(or alkyl)-N-(3-aralkyl-2-thio-1-hydantoinyl)-2H-1,2-benyothiazine-3-carboxamide 1,1-dioxide derivs. were synthesized through the condensation of 7-halo-4-hydroxy-2H(or alkyl)-1,2-benzothiazine-3-carboxylic acid Me ester 1,1-dioxides with 1-amino-2-thio-3-aralkylimidazolidine-4-ones. The analgesic and anti-inflammatory activities of the synthesized compds. were investigated by acetic acid-induced writhing syndrome and carrageenan rat paw edema tests. In analgesic activities most compds. exhibited higher activities than acetylsalicylic acid, but in anti-inflammatory activities most compds. except 3 of them showed lower activities than indomethacin.
IT **183859-51-0P 183859-52-1P 183859-54-3P 183859-55-4P 183859-64-5P 183859-65-6P 183859-66-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and analgesic and anti-inflammatory activities of benzothiazine derivs.)
RN 183859-51-0 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-(3-methyl-4-oxo-2-thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-52-1 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-54-3 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-[3-(4-chlorophenyl)-4-oxo-2-
thioxo-1-imidazolidinyl]-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-55-4 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-64-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-(3-methyl-4-oxo-2-
thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-65-6 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 183859-66-7 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-(4-oxo-3-phenyl-2-
thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:449321 CAPLUS
DN 119:49321
TI The synthesis of 1,2-benzothiazine-3-carboxamidylhydantoin derivatives and their antiinflammatory and analgesic activities
AU Kwon, Soon Kyoung; Park, Myoung Suk
CS Coll. Pharm., Duksung Women's Univ., Seoul, 132-714, S. Korea
SO Archives of Pharmacal Research (1992), 15(3), 251-5
CODEN: APHRDQ; ISSN: 0253-6269
DT Journal
LA English
OS CASREACT 119:49321
GI



I

AB Twenty-one 4-hydroxy-2H (or alkyl)-N-(3-aralkyl-2-thio-1-hydantoinyl)-1,2-benzothiazine-3-carboxamide 1,1-dioxides, e.g., I, were synthesized through the reaction of 4-hydroxy-2H (or alkyl)-1,2-benzothiazine-3-carboxylic Me ester 1,1-dioxides and 1-amino-2-thio-3-aralkyl-4-imidazolones in xylene. The compds. synthesized were screened for antiinflammatory effect on carrageenin-induced edema in rat and for analgesic effect on acetic acid-induced writhing syndrome in mice. Most compds. were inhibitors of carrageenin-induced rat foot edema and some showed significant antiinflammatory activity comparable to that of indomethacin and significant analgesic activity comparable to that of indomethacin and aspirin.

IT **148316-43-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antiinflammatory and analgesic activity of)
RN 148316-43-2 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-[3-(4-chlorophenyl)-4-oxo-2-thioxo-1-imidazolidinyl]-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:472742 CAPLUS
DN 101:72742
TI 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, its use, and pharmaceuticals containing these compounds
IN Trummlitz, Guenter; Engel, Wolfhard; Seeger, Ernst; Haarmann, Walter
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 32 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3237473	A1	19840412	DE 1982-3237473	19821009
	EP 106214	A1	19840425	EP 1983-109512	19830924
	EP 106214	B1	19851204		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	AT 16807	E	19851215	AT 1983-109512	19830924
	US 4533664	A	19850806	US 1983-537592	19830930
	FI 8303566	A	19840410	FI 1983-3566	19831003
	SU 1148565	A3	19850330	SU 1983-3654490	19831005
	DK 8304607	A	19840410	DK 1983-4607	19831006
	DD 215549	A5	19841114	DD 1983-255478	19831006
	NO 8303665	A	19840410	NO 1983-3665	19831007
	AU 8319986	A1	19840412	AU 1983-19986	19831007
	GB 2128190	A1	19840426	GB 1983-26876	19831007
	GB 2128190	B2	19860702		
	JP 59088482	A2	19840522	JP 1983-188284	19831007
	ES 526332	A1	19841116	ES 1983-526332	19831007
	HU 34472	A2	19850328	HU 1983-3482	19831007
	HU 190169	B	19860828		
	CS 236896	B2	19850515	CS 1983-7378	19831007
	ZA 8307500	A	19850626	ZA 1983-7500	19831007
	CA 1207767	A1	19860715	CA 1983-438617	19831007
	PL 139147	B1	19861231	PL 1983-244080	19831007
	IL 69931	A1	19870331	IL 1983-69931	19831007
	ES 531402	A1	19841216	ES 1984-531402	19840409
PRAI	DE 1982-3237473		19821009		
	EP 1983-109512		19830924		

OS CASREACT 101:72742
GI



I

AB The title compds. (I; R = H, Me, MeO, Cl, F; R1 = H, Me, Et, Pr) were prepd. Thus, Me 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide was refluxed 24 h in C6H4Me2 with 2-amino-6-chloropyrazine to give 64% I (R = H, R1 = Me) (II). In mice 10 mg II/kg orally increased bleeding time 103%.

IT **91286-70-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(prepn., ethylation, and methylation of)

RN 91286-70-3 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(6-chloropyrazinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:472175 CAPLUS
DN 83:72175
TI Benzothiazine dioxides as antithrombotic agents
IN Lombardino, Joseph G.; Wiseman, Edward A.
PA Pfizer, Inc.
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3862319	A	19750121	US 1973-362518	19730521
PRAI	US 1969-829713		19690602		
	US 1971-114037		19710209		

GI For diagram(s), see printed CA Issue.
AB Compds. of the general structures I and II were effective antithrombotic agents. Physiol. testing data in animals and man was given.
IT **56209-19-9**
RL: BIOL (Biological study)
(antithrombotic)
RN 56209-19-9 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(5-chloro-2-pyridinyl)-3,4-dihydro-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7784248
Molec. Formula (MF):	C19 H15 Br N4 O5 S2
Molecular Weight (MW):	523.38
Lawson Number (LN):	31458, 28769, 14140
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6631776
Tautomer ID (TAUTID):	7358730
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7783321
Molec. Formula (MF):	C18 H13 Br N4 O5 S2
Molecular Weight (MW):	509.35
Lawson Number (LN):	31458, 28769, 14131
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6629621
Tautomer ID (TAUTID):	7358136
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7783308
Molec. Formula (MF):	C18 H13 Cl N4 O5 S2
Molecular Weight (MW):	464.90
Lawson Number (LN):	31458, 28769, 14131
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6628019
Tautomer ID (TAUTID):	7357920
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7782315
Molec. Formula (MF):	C15 H13 Br N4 O5 S2
Molecular Weight (MW):	473.32
Lawson Number (LN):	31458, 28769, 2947
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6627609
Tautomer ID (TAUTID):	7357341
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7782314
Molec. Formula (MF):	C15 H13 Cl N4 O5 S2
Molecular Weight (MW):	428.86
Lawson Number (LN):	31458, 28769, 2947
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6627686
Tautomer ID (TAUTID):	7357707
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7781525
Molec. Formula (MF):	C13 H11 Br N4 O5 S2
Molecular Weight (MW):	447.28
Lawson Number (LN):	31458, 28769, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6622740
Tautomer ID (TAUTID):	7354727
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

L8 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL on STN

Beilstein Records (BRN):	7781524
Molec. Formula (MF):	C13 H11 Cl N4 O5 S2
Molecular Weight (MW):	402.83
Lawson Number (LN):	31458, 28769, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6621898
Tautomer ID (TAUTID):	7355053
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, Arzneim.Forsch., CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:19:02 ON 23 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:11 ON 23 JUL 2003
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 19 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:19:42 ON 23 JUL 2003
L4 8 S L3

FILE 'BEILSTEIN' ENTERED AT 15:20:28 ON 23 JUL 2003
L5 2 S L1
L6 8 S L1 FUL
L7 8 S L6 NOT L4
L8 8 S L6 NOT L3

FILE 'MARPAT' ENTERED AT 15:21:34 ON 23 JUL 2003

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	454.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.21

STN INTERNATIONAL LOGOFF AT 15:21:49 ON 23 JUL 2003